PRAGUE-6: off-pump versus in-pump CABG in high-risk patients

Coronary artery bypass grafting (CABG) without a cardiopulmonary bypass, (CBP), has increasingly become an alternative to the conventional standard (with pump). However, it is still controversial whether there is a decrease in morbidity and mortality between these two techniques. The aim of this study was to compare these two techniques in a high risk population. 

A prospective study where 206 patients were randomized with a EuroSCORE of less than 6 to in-pump CABG, (n = 108), and without CPB, (n = 98). There were no significant differences in clinical characteristics and procedure between the groups. The average age was 74 years with a logistic mean EuroSCORE of 7.66 in the CPB group and 7.69 in the off-pump group. The primary endpoint, (a composite of death, AMI, stroke, acute renal failure requiring dialysis), at thirty days was 20.6% with pump and 9.2% in the off-pump group, (p = 0.028, RR 0,41 [0.19 to 0.91]). The pump group also required more transfusions, (80.2% versus 64.9%). 

Conclusion: In patients with a high surgical risk, CBP surgery is a safer way of direct revascularization due to the lower incidence of primary endpoints and a lower rate of transfusions. 

Comments: This study, unlike the study results presented in the GOPCABE trial just minutes earlier, shows that patients with a high surgical risk benefit from the less invasive technique. These contradictory results lead us to conclude that the results should be interpreted with caution, reinforcing the importance of standardization, an improvement of the technique and the proper selection of patients.

jan_hlavicka_acc2013
Jan Hlavicka
2013-03-11

Original title: PRAGUE-6 Trial: Off-Pump Versus On-Pump Coronary Artery Bypass Graft Surgery in Patients with EuroSCORE ≥6.

More articles by this author

PARTNER cohort A at three years, the benefit continues

The PARTNER Cohort A randomized 699 elderly patients, (mean age 84.1), with severe aortic stenosis for TAVI or conventional surgery in 26 centers. The...

ASTRONAUT: Aliskiren failed to show benefits in patients with acute heart failure

Hospitalization for heart failure, (HF), represents a major health problem with high rates of death or early readmission after discharge. The aim of this...

RELAX Study: Phosphodieserase-5 inhibitors showed no benefit in heart failure with preserved ventricular function.

Phosphodieserase-5 enzyme is activated in heart failure and can limit the beneficial effects of nitric oxide, (NO), in the vasculature, kidney and myocardium. The...

STOP-HF: The use of B-type natriuretic peptide (BNP) for screening high-risk population decreases the prevalence of heart failure

B-type natriuretic peptide (BNP) can be a reliable marker for the diagnosis of heart failure (HF). This study aimed to assess whether the use...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....